89Zr-nivolumab

89锆-纳武利尤单抗

Report date: 2025/11/24 11:49:45

Base Information

Drug Name89Zr-nivolumab
Drug Alias Name锆[89Zr]-纳武利尤单抗89Zr-nivolumab89Zr-BMS-936558
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanRadiation-emitting products > Nuclides > Zirconium > 89ZrRadiation-emitting products > Radionuclide Drug Conjugates +[6] 
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol-Myers Squibb Company
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A